Longevity Supplements: What the Evidence Actually Shows

The longevity supplement market is enormous, growing rapidly, and largely built on a foundation of animal studies, mechanistic plausibility, and aggressive marketing.

That is not a reason to dismiss it entirely. Some of the science is genuinely interesting. Some compounds have real biological effects. But the gap between what the research shows and what the marketing claims is wide, and navigating it requires understanding what kinds of evidence actually matter.

This is an honest assessment of the most discussed longevity compounds, categorized by the strength of the evidence behind them.

Before evaluating specific compounds, it is worth being clear about what different types of evidence mean.

Animal studies are the starting point for most longevity research. They are valuable for identifying mechanisms and generating hypotheses, but they translate to humans poorly. Many compounds that extend lifespan in mice have failed to show similar effects in humans. The biology of aging in short-lived organisms like mice differs substantially from human aging.

Mechanistic studies in humans show that a compound affects a biological pathway thought to be relevant to aging. This is more meaningful than animal data but does not establish that the effect translates to clinical outcomes.

Randomized controlled trials (RCTs) in humans with clinical endpoints are the gold standard. For longevity research, these are rare, expensive, and difficult to conduct because the relevant endpoints, lifespan and healthspan, take decades to measure.

With that framework in mind, here is where the major longevity compounds stand.

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme involved in hundreds of metabolic reactions and plays a central role in DNA repair, mitochondrial function, and the activity of sirtuins, proteins implicated in aging regulation. NAD+ levels decline with age, and this decline is thought to contribute to multiple aspects of biological aging.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors that raise NAD+ levels. Animal studies have shown impressive results: NAD+ precursors extend lifespan in mice, improve metabolic function, and reverse some age-related physiological declines.

Human data is more limited but emerging. Several small RCTs have confirmed that NMN and NR supplementation raises NAD+ levels in human blood and tissues. A 2021 study found that NMN supplementation improved muscle insulin sensitivity in postmenopausal women with prediabetes. A 2022 study found improvements in physical performance metrics in older adults.

Assessment: Promising. The mechanistic rationale is strong, the safety profile appears favorable, and early human data is encouraging. But large RCTs with clinical endpoints do not yet exist. The animal data is more impressive than the human data, and the translation is uncertain.

Resveratrol, a polyphenol found in red wine and grapes, generated enormous excitement in the mid-2000s when studies showed it activated sirtuins and extended lifespan in yeast, worms, and mice. The popular press declared it the active ingredient in red wine's health benefits.

The subsequent human research has been considerably less impressive. Multiple large RCTs have failed to find meaningful clinical benefits of resveratrol supplementation in humans. A 2014 study in JAMA Internal Medicine found that higher urinary resveratrol metabolites (a marker of dietary resveratrol intake) were not associated with reduced cardiovascular disease, cancer, or mortality in a population of older adults.

The bioavailability of resveratrol is poor: it is rapidly metabolized and cleared, and the blood levels achieved with typical supplementation are far lower than those used in animal studies.

Assessment: Not ready. The mechanistic story is interesting, but the human clinical evidence does not support supplementation for longevity. Eating polyphenol-rich foods, including those that contain resveratrol, is supported by dietary pattern research, but isolated resveratrol supplements are not.

Rapamycin is an immunosuppressant drug that inhibits mTOR (mechanistic target of rapamycin), a signaling pathway that regulates cell growth, metabolism, and autophagy. Inhibiting mTOR mimics some of the effects of caloric restriction and has extended lifespan in every organism tested, including mice, even when started late in life.

Rapamycin is not a supplement; it is a prescription drug with significant side effects including immunosuppression, impaired wound healing, and metabolic effects. It is used clinically to prevent organ transplant rejection.

Some longevity physicians are prescribing rapamycin off-label at low intermittent doses, arguing that the side effect profile at these doses is more favorable than at the doses used for immunosuppression. The evidence for this approach in humans is limited to observational data and small studies.

Assessment: Emerging, with significant caveats. The mechanistic and animal evidence is the strongest of any longevity compound. Human evidence is limited. The risk-benefit calculation at low doses is genuinely uncertain and requires careful clinical judgment. This is not a self-prescribe situation.

Metformin is a diabetes drug with decades of safety data that has shown intriguing associations with reduced cancer risk, cardiovascular disease, and all-cause mortality in diabetic populations. The TAME (Targeting Aging with Metformin) trial, a large multi-site RCT, is currently underway to test whether metformin delays aging-related conditions in non-diabetic older adults.

The mechanisms are multiple: metformin activates AMPK (an energy-sensing enzyme that promotes cellular maintenance), reduces mTOR signaling, and has anti-inflammatory effects.

Assessment: Promising, awaiting definitive evidence. The observational data is encouraging, the mechanistic rationale is solid, and the safety profile is well-established. The TAME trial results will be important. Like rapamycin, this is a prescription drug that requires clinical oversight.

Vitamin D deficiency is common, particularly in older adults and in people with limited sun exposure. Deficiency is associated with increased risk of cardiovascular disease, cancer, cognitive decline, and all-cause mortality.

The evidence for supplementation in deficient individuals is reasonably strong. The evidence for supplementation in people with adequate levels is less clear. A large RCT (VITAL) found that vitamin D supplementation reduced cancer mortality but did not significantly reduce cardiovascular events in a general population.

Assessment: Proven for deficiency correction. Testing vitamin D levels and supplementing to correct deficiency is evidence-based. Supplementing in people with adequate levels for longevity purposes has weaker support.

Omega-3 fatty acids (EPA and DHA, found in fatty fish and fish oil supplements) have anti-inflammatory effects and are associated with reduced cardiovascular risk in observational studies. The VITAL trial found that omega-3 supplementation reduced cardiovascular events in people who did not eat fish regularly.

Assessment: Proven for specific populations. The evidence for omega-3s in cardiovascular risk reduction is reasonably strong, particularly for people with low dietary fish intake. The evidence for broader longevity effects is more limited.

The longevity supplement space is characterized by a large gap between mechanistic excitement and clinical evidence. The compounds with the most impressive animal data (rapamycin, NMN) have the least human clinical evidence. The compounds with the most human evidence (vitamin D, omega-3s) are the least exciting mechanistically.

This does not mean supplements are useless. It means that the evidence should guide expectations. Correcting documented deficiencies is evidence-based. Taking compounds with strong mechanistic rationale and emerging human data (NMN, NR) is a reasonable personal decision with the understanding that the evidence is preliminary. Taking compounds with poor human evidence (resveratrol) based on animal data and marketing is not.

The interventions with the strongest evidence for longevity remain the unglamorous ones: exercise, sleep, diet, stress management, and not smoking. No supplement comes close to matching their effect size.

The Ultimate Anti-Aging Blueprint covers the evidence on supplements and pharmaceuticals in the context of a comprehensive longevity framework, with honest assessments of what is proven, promising, and not ready.